In this Q&A, Alana Gouveia of MilliporeSigma discusses the challenges that formulators face when lowering the viscosity of injectable drug products and explains how MilliporeSigma’s SAFC® Viscosity Reduction Platform helps manufacturers achieve appropriate viscosity while maintaining protein stability to achieve optimum results and meet customer needs.
.svg)
